Eli Lilly and Company (LLY)vsOmniAb Inc. (OABI)
LLY
Eli Lilly and Company
$1,417.54
+3.19%
HEALTHCARE · Cap: $1.26T
OABI
OmniAb Inc.
$5.11
-2.29%
HEALTHCARE · Cap: $677.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 224728% more annual revenue ($86.46B vs $38.46M). LLY leads profitability with a 31.9% profit margin vs -115.1%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
OABI
Hold37
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Revenue surging 244.2% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : OABI
The strongest argument for OABI centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 244.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while OABI is a hypergrowth play — different risk/reward profiles.
OABI carries more volatility with a beta of 1.37 — expect wider price swings.
OABI is growing revenue faster at 244.2% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 37/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?